Research
Hormonal
Semaglutide and tirzepatide improve symptoms and functional capacity in obesity-related heart failure of preserved ejection fraction and reduce worsening heart failure events.
Practitioners can use semaglutide and tirzepatide to improve heart failure symptoms in patients with obesity.
StrongSupportsmedium confidence
In obesity-related heart failure of preserved ejection fraction, semaglutide and tirzepatide improve symptoms and functional capacity and reduce worsening heart failure events.
Why this rating
Based on the outcomes mentioned in the context of obesity-related heart failure.
Source
Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery
Itxaso K Villelabeitia et al. · Heart · 2026
Meta-analysisCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →